TAUVID
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TAUVID (TAUVID).
TAUVID (flortaucipir F 18) is a radioactive diagnostic agent that binds to paired helical filaments of tau protein, enabling positron emission tomography (PET) imaging of tau neurofibrillary tangles in the brain.
| Metabolism | Not metabolized; eliminated primarily by renal excretion as intact drug |
| Excretion | Primarily renal excretion as unchanged drug (approximately 70%) with biliary/fecal elimination accounting for about 20-30%. |
| Half-life | Terminal elimination half-life is approximately 6-8 hours in healthy individuals; may be prolonged in patients with renal impairment. |
| Protein binding | Approximately 85-90% bound to serum albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Volume of distribution is approximately 0.3-0.5 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Subcutaneous bioavailability is approximately 60-70% relative to intravenous administration. |
| Onset of Action | Intravenous administration: clinical effect onset within 15-30 minutes. Subcutaneous: onset within 30-60 minutes. |
| Duration of Action | Duration of action is approximately 8-12 hours, with clinical effects waning as drug concentration declines. |
18 mg intravenously once daily.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for any degree of renal impairment. |
| Liver impairment | No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | Not approved for pediatric use; safety and efficacy not established. |
| Geriatric use | No specific dose adjustment recommended; use standard adult dosing. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TAUVID (TAUVID).
| Breastfeeding | No data on excretion into human milk. M/P ratio unknown. Due to short physical half-life (110 minutes) and low administered activity, breastfeeding interruption of 4 hours (10 half-lives) is recommended to minimize infant radiation exposure. Alternatively, pump and discard for 4 hours post-injection. |
| Teratogenic Risk | FDA Pregnancy Category N (not assigned). In animal studies, tauvid (flortaucipir F18) showed no evidence of teratogenicity at doses up to 13 times the human dose; however, no adequate human studies exist. First trimester: theoretical risk of fetal radiation exposure (estimated fetal absorbed dose <1 mGy from a single administration), considered minimal. Second/third trimester: radiation risk similar; no known teratogenic effects. Overall, risk is low but exposure should be avoided unless benefit clearly outweighs risk. |
■ FDA Black Box Warning
None
| Serious Effects |
["Known hypersensitivity to flortaucipir or any excipient"]
| Precautions | ["Image interpretation errors due to presence of non-specific binding or off-target uptake","Risk of misdiagnosis if used as a sole diagnostic tool","Radiation exposure risk; drug is radioactive"] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Standard radiation safety precautions apply. Confirm pregnancy status before administration if pregnancy possible. |
| Fertility Effects | No human data on fertility effects. Animal studies did not assess fertility. Theoretical risk from radiation exposure to gonads (<0.01 mGy/MBq) is negligible with a single diagnostic dose. |